[Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice].
Vladimir VorobyevE G GemdzhianLiudmila V FedorovaN B MikhailovaR K IlyasovL P KaleikinaO S TrubyakovaKamil D KaplanovE V MelnichenkoE V MartynovaE P YakovlevaO Y LiE V TarasenkoE P ChumakovaN B BulievaE S NesterovaO V MargolinV A ZherebtsovaL S ButaevVadim V PtushkinPublished in: Terapevticheskii arkhiv (2021)
Ibrutinib is effective and well tolerated in routine practice of R/R MCL treatment and our results are consistent with international clinical trials. The favorable toxicity profile and the high response rate made it possible to prescribe ibrutinib in severe somatic status, cytopenia, and even in the presence of infectious complications.